Shawn W. Foley
YOU?
Author Swipe
View article: Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Supplementary Tables
View article: Supplemental Figure from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Supplemental Figure from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Supplemental Figure
View article: Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Supplementary Methods
View article: Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Supplementary Methods
View article: Supplemental Figure from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Supplemental Figure from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Supplemental Figure
View article: Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Supplementary Methods
View article: Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Supplementary Tables
View article: Supplemental Figure from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Supplemental Figure from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Supplemental Figure
View article: Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Supplementary Tables
View article: Data from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Data from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Purpose:Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment of hematologi…
View article: Table S2 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Table S2 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
Antibody List
View article: Table S3 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Table S3 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
shRNA
View article: Table S3 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Table S3 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
shRNA
View article: Table S2 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Table S2 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
Antibody List
View article: Supplementary Figure S3 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Supplementary Figure S3 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
LIN28B-S in Huh7.5 cells
View article: Data from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Data from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
The RNA-binding protein LIN28B plays an important role in development, stem cell biology, and tumorigenesis. LIN28B has two isoforms: the LIN28B-long and -short isoforms. Although studies have revealed the functions of the LIN28B-long isof…
View article: Supplementary Figure S2 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Supplementary Figure S2 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
LIN28B mRNA expression in human CRC samples
View article: Supplementary Figure S2 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Supplementary Figure S2 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
LIN28B mRNA expression in human CRC samples
View article: Data from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Data from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
The RNA-binding protein LIN28B plays an important role in development, stem cell biology, and tumorigenesis. LIN28B has two isoforms: the LIN28B-long and -short isoforms. Although studies have revealed the functions of the LIN28B-long isof…
View article: Table S1 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Table S1 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
qPCR primers
View article: Supplementary Figure S3 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Supplementary Figure S3 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
LIN28B-S in Huh7.5 cells
View article: Supplementary Figure S1 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Supplementary Figure S1 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
LIN28B short isoform in Huh7.5 cell
View article: Supplementary Figure S1 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Supplementary Figure S1 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
LIN28B short isoform in Huh7.5 cell
View article: Table S1 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions
Table S1 from Differential Regulation of <i>LET-7</i> by LIN28B Isoform–Specific Functions Open
qPCR primers
View article: Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Supplementary Methods
View article: Data from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Data from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Purpose:Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment of hematologi…
View article: Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Supplementary Tables
View article: Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Supplementary Tables
View article: Data from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Data from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Purpose:Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment of hematologi…
View article: Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies Open
Supplementary Methods